Cargando…

Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants

IMPORTANCE: The CHA(2)DS(2)-VASc score (calculated as congestive heart failure, hypertension, age 75 years and older, diabetes, stroke or TIA, vascular disease, age 65 to 74 years, and sex category) is the standard for assessing risk of stroke and systemic embolism and includes age and thromboemboli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lip, Gregory Y. H., Murphy, Richard R., Sahiar, Farhad, Ingall, Timothy J., Dhamane, Amol D., Ferri, Mauricio, Hlavacek, Patrick, Preib, Madison T., Keshishian, Allison, Russ, Cristina, Rosenblatt, Lisa, Yuce, Huseyin, Deitelzweig, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434362/ https://www.ncbi.nlm.nih.gov/pubmed/36044214 http://dx.doi.org/10.1001/jamanetworkopen.2022.29333

Ejemplares similares

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients
por: Deitelzweig, Steven, et al.
Publicado: (2019)

Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States
por: Deitelzweig, Steven, et al.
Publicado: (2020)

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
por: Dhamane, Amol D., et al.
Publicado: (2022)

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
por: Dhamane, Amol D, et al.
Publicado: (2021)

Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants
por: Baker, Christine L., et al.
Publicado: (2019)

Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population
por: Amin, Alpesh, et al.
Publicado: (2019)

Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study
por: Deitelzweig, Steve, et al.
Publicado: (2020)

Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States
por: Baker, Christine L., et al.
Publicado: (2018)

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients: The ARISTOPHANES Study
por: Lip, Gregory Y.H., et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
por: Cohen, Alexander T., et al.
Publicado: (2021)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database
por: Munir, Muhammad Bilal, et al.
Publicado: (2022)

Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure
por: Amin, Alpesh, et al.
Publicado: (2019)

Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database
por: Munir, Muhammad Bilal, et al.
Publicado: (2022)

Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States
por: Turakhia, Mintu P., et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants
por: Deitelzweig, Steve, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation
por: Atwater, Brett D., et al.
Publicado: (2023)

Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population
por: Gupta, Kiran, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population
por: Amin, Alpesh, et al.
Publicado: (2018)

A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population
por: Amin, Alpesh, et al.
Publicado: (2020)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach
por: Li, Xiaoyan, et al.
Publicado: (2018)

Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation
por: Sen, Souvik, et al.
Publicado: (2014)

National Physician Survey for Nonvalvular Atrial Fibrillation (NVAF) Anticoagulation Comparing Knowledge, Attitudes and Practice of Cardiologist to PCPs
por: Saeed, Haseeb, et al.
Publicado: (2020)

Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
por: Ferro, D., et al.
Publicado: (2007)

Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021)

Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis
por: Wang, Kang-Ling, et al.
Publicado: (2015)

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
por: Pham, Phuong, et al.
Publicado: (2020)

Anticoagulant Therapy in Initially Low‐Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors
por: Choi, Sun Young, et al.
Publicado: (2020)

Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2022)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Anticoagulants in Older Patients with Nonvalvular Atrial Fibrillation after Intracranial Hemorrhage
por: Perreault, Sylvie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ksl92a2irdsbc0v2l7gpnt1spq